Clinical Utility of LIBS Multi-Element Imaging and the IFF Algorithm in Chronic Lung Diseases (PNEUMO-LIBS)
Evaluation of the Clinical Utility of LIBS Multi-Element Imaging and the IFF Algorithm for the Etiological and Medico-Legal Management of Chronic Lung Diseases
PNEUMO-LIBS is a multicenter, non-interventional observational study designed to evaluate whether multi-element tissue imaging by Laser-Induced Breakdown Spectroscopy (LIBS), combined with an artificial intelligence-based analysis tool called Interesting Features Finder (IFF), may help physicians better understand the possible causes of chronic lung diseases.
The study focuses on adult patients with chronic lung diseases for which a lung biopsy has already been performed as part of routine medical care. These diseases include diffuse interstitial lung diseases, pulmonary granulomatoses such as sarcoidosis, and emphysema, especially when an environmental or occupational exposure is suspected but not clearly demonstrated.
Some chronic lung diseases may be influenced by inhaled mineral or metallic particles, such as silica, aluminum, titanium, or other metals. However, these exposures are often difficult to document at the individual patient level. Standard clinical, radiological, and pathological investigations do not usually provide direct information on the presence and distribution of such elements within lung tissue.
LIBS is an imaging technique that can detect and map chemical elements directly in tissue samples, including archived formalin-fixed paraffin-embedded biopsy blocks. In this study, lung biopsy samples will be analyzed with LIBS to search for elemental signatures that may be compatible with occupational or environmental exposures. The IFF algorithm will then be used to help interpret the LIBS data and identify rare or unexpected elemental signals.
The study does not require any additional biopsy, blood test, imaging examination, treatment, or hospital visit for participants. It uses tissue samples and medical data already collected during routine care. The results of LIBS and IFF analyses will be presented to the treating physician or investigator, who will complete standardized online questionnaires at three time points: before receiving the LIBS results, after receiving the LIBS report, and after receiving the IFF-assisted interpretation.
The main objective is to assess the perceived clinical utility of LIBS imaging for physicians, particularly regarding etiological understanding, possible occupational disease recognition, and prevention-oriented reasoning. Secondary objectives include assessing the added value of the IFF algorithm and evaluating the feasibility of a centralized multicenter workflow for sample transfer, LIBS analysis, IFF processing, result reporting, and questionnaire completion.
The study aims to include approximately 70 patients across several French hospital centers. Its results may support the development of future diagnostic, occupational health, and environmental medicine approaches, without modifying the medical care of participants during the study.
Studienübersicht
Status
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Benoit BUSSER
- Telefonnummer: +33476768939
- E-Mail: BBusser@chu-grenoble.fr
Studieren Sie die Kontaktsicherung
- Name: Vincent BONNETERRE
- Telefonnummer: +33476765851
- E-Mail: VBonneterre@chu-grenoble.fr
Studienorte
-
-
-
Grenoble, Frankreich
- Rekrutierung
- CHU Grenoble Alpes
-
Kontakt:
- Benoit BUSSER
- Telefonnummer: +33476768939
- E-Mail: BBusser@chu-grenoble.fr
-
Kontakt:
- Vincent BONNETERRE
- Telefonnummer: 33+ (0)4 76 76 58 51
- E-Mail: VBonneterre@chu-grenoble.fr
-
Nancy, Frankreich
- Rekrutierung
- Centre Hospitalier Régional Universitaire Nancy (CHRU)
-
Kontakt:
- Isabelle THAON
- Telefonnummer: 33 3 83 15 71 71
- E-Mail: i.thaon@chru-nancy.fr
-
Hauptermittler:
- Isabelle THAON
-
Rouen, Frankreich
- Rekrutierung
- centre Hospitalier Universitaire Rouen (CHU)
-
Kontakt:
- Antoine GISLARD
- Telefonnummer: 33 2 35 88 82 69
- E-Mail: Antoine.Gislard@chu-rouen.fr
-
Hauptermittler:
- Antoine GISLARD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Adult patient aged 18 years or older.
- Diagnosis or documented clinical suspicion of chronic lung disease, including interstitial lung disease, pulmonary granulomatosis such as sarcoidosis, or pulmonary emphysema.
- Availability of a lung tissue biopsy sample obtained during routine medical care and stored as a formalin-fixed paraffin-embedded sample.
- Sufficient medical record information to document the clinical context, occupational or environmental exposure history, smoking status, imaging, pathology reports, and other relevant routine-care data.
- No documented objection to the secondary use of health data and biological samples for this research.
Exclusion Criteria:
- Documented objection to participation in the study or to the secondary use of health data or biological samples for research.
- Missing, unavailable, degraded, or technically unusable biopsy sample.
- Insufficient medical record information to document the clinical context or exposure history.
- Lung condition outside the scope of the study, such as isolated acute infection, isolated cardiac disease, or primary lung cancer.
- Patient under legal protection when the applicable legal conditions for non-opposition cannot be fulfilled.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Patients With Perceived Added Clinical Value of LIBS Imaging
Zeitfenster: After Review of the LIBS Report, Up to 1 Month After Inclusion
|
Proportion of patients for whom the investigator reports that LIBS imaging provides new and clinically useful information in at least one of the following domains: etiological understanding, medico-legal reasoning regarding possible occupational disease recognition, or prevention-oriented recommendations.
|
After Review of the LIBS Report, Up to 1 Month After Inclusion
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Vincent BONNETERRE, CHU Grenoble Alpes
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 38RC26.0001
- 2026-A00164-47 (Andere Kennung: ID RCB)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .